Protriptyline - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (2)Enzymes (1)Transporters (1)

Targets (2)Enzymes (1)Transporters (1)Biointeractions (4)

Identification

Name

Protriptyline

Accession Number

DB00344 (APRD00441)

Type

Small Molecule

Groups

Approved

Description

Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H₁ receptors, α₁-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Protriptyline may be used for the treatment of depression.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine

3-(5H-Dibenzo[a,D]cyclohepten-5-yl)-N-methyl-1-propanamine

5-(3-Methylaminopropyl)-5H-dibenzo[a,D]cycloheptene

7-(3-Methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene

Amimetilina

N-Methyl-5H-dibenzo[a,D]cycloheptene-5-propanamine

N-Methyl-5H-dibenzo[a,D]cycloheptene-5-propylamine

Protriptilina

Protriptylin

Protriptyline

Protriptylinum

External IDs

MK 240 / MK-240

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Protriptyline hydrochloride	44665V00O8	1225-55-4	OGQDIIKRQRZXJH-UHFFFAOYSA-N	Details

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Triptil Tab 10mg	Tablet	10 mg	Oral	Merck Frosst Canada & Cie, Merck Frosst Canada & Co.	1966-12-31	2001-01-25	Canada

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Protriptyline Hydrochloride	Tablet, film coated	5 mg/1	Oral	Epic Pharma, LLC	2013-01-09	Not applicable	US
Protriptyline hydrochloride	Tablet, film coated	10 mg/1	Oral	Hi Tech Pharmacal Co., Inc.	2013-10-28	Not applicable	US
Protriptyline Hydrochloride	Tablet	5 mg/1	Oral	West Ward Pharmaceutical	2008-09-16	Not applicable	US
Protriptyline Hydrochloride	Tablet, film coated	10 mg/1	Oral	Epic Pharma, LLC	2013-01-09	Not applicable	US
Protriptyline Hydrochloride	Tablet, film coated	5 mg/1	Oral	Rising Pharmaceuticals	2010-06-11	Not applicable	US
Protriptyline Hydrochloride	Tablet	10 mg/1	Oral	West Ward Pharmaceutical	2008-09-16	Not applicable	US
Protriptyline hydrochloride	Tablet, film coated	5 mg/1	Oral	Hi Tech Pharmacal Co., Inc.	2013-10-28	Not applicable	US
Protriptyline Hydrochloride	Tablet, film coated	10 mg/1	Oral	Rising Pharmaceuticals	2010-06-11	Not applicable	US

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Triptil	Not Available
Vivactil	Odyssey

Brand mixtures

Not Available

Categories

UNII

4NDU154T12

CAS number

438-60-8

Weight

Average: 263.3767
Monoisotopic: 263.167399677

Chemical Formula

C₁₉H₂₁N

InChI Key

BWPIARFWQZKAIA-UHFFFAOYSA-N

InChI

InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-10,12-13,19-20H,6,11,14H2,1H3

IUPAC Name

methyl(3-{tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-yl}propyl)amine

SMILES

CNCCCC1C2=CC=CC=C2C=CC2=CC=CC=C12

Pharmacology

Indication

For the treatment of depression.

Structured Indications

Depressive State

Pharmacodynamics

Protriptyline is a tricyclic antidepressant. It was thought that tricyclic antidepressants work by inhibiting the reuptake of the neurotransmitters norepinephrine and serotonin by nerve cells. However, this response occurs immediately, yet mood does not lift for approximately two weeks. It is now thought that changes occur in receptor sensitivity in the cerebral cortex and hippocampus. The hippocampus is part of the limbic system, a part of the brain involved in emotions. Presynaptic receptors are affected: α₁ and β₁ receptors are sensitized, α₂ receptors are desensitised (leading to increased noradrenaline production). Tricyclics are also known as effective analgesics for different types of pain, especially neuropathic or neuralgic pain. A precise mechanism for their analgesic action is unknown, but it is thought that they modulate anti-pain opioid systems in the CNS via an indirect serotonergic route. They are also effective in migraine prophylaxis, but not in abortion of acute migraine attack. The mechanism of their anti-migraine action is also thought to be serotonergic.

Mechanism of action

Protriptyline acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Sodium-dependent noradrenaline transporter	Protein	yes	inhibitor	Human	P23975	details
Sodium-dependent serotonin transporter	Protein	yes	inhibitor	Human	P31645	details

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Cumulative urinary excretion during 16 days accounted for approximately 50% of the drug. The fecal route of excretion did not seem to be important.

Half life

Not Available

Clearance

Not Available

Toxicity

Side effects include anxiety, blood disorders, confusion, decreased libido, dizziness, flushing, headache, impotence, insomnia, low blood pressure, nightmares, rapid or irregular heartbeat, rash, seizures, sensitivity to sunlight, stomach and intestinal discomfort, sedation, hypotension, blurred vision, dry mouth, constipation, urinary retention, postural hypotension, tachycardia, hypertension, ECG changes, heart failure, impaired memory and delirium, and precipitation of hypomanic or manic episodes in bipolar depression. Withdrawal symptoms include gastrointestinal disturbances, anxiety, and insomnia.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Interacting Gene/Enzyme	Allele name	Genotype(s)	Defining Change(s)	Type(s)	Description	Details
Cytochrome P450 2D6	CYP2D6*3	Not Available	C allele	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*4	Not Available	C allele	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*5	Not Available	Whole-gene deletion	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*6	Not Available	1707delT	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*7	Not Available	2935A>C	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*8	Not Available	1758G>T	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*11	Not Available	883G>C	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*12	Not Available	124G>A	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*13	Not Available	CYP2D7/2D6 hybrid gene structure	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*14A	Not Available	1758G>A	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*15	Not Available	137insT, 137_138insT	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*19	Not Available	2539_2542delAACT	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*20	Not Available	1973_1974insG	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*21	Not Available	2573insC	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*31	Not Available	-1770G>A / -1584C>G … show all	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*36	Not Available	100C>T / -1426C>T … show all	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*38	Not Available	2587_2590delGACT	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*40	Not Available	1863_1864ins(TTT CGC CCC)2	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*42	Not Available	3259_3260insGT	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*44	Not Available	2950G>C	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*47	Not Available	100C>T / -1426C>T … show all	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*51	Not Available	-1584C>G / -1235A>G … show all	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*56	Not Available	3201C>T	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*57	Not Available	100C>T / 310G>T … show all	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*62	Not Available	4044C>T	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*68A	Not Available	-1426C>T / -1235A>G … show all	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*68B	Not Available	Similar but not identical switch region compared to CYP2D668A. Found in tandem arrangement with CYP2D64.	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*69	Not Available	2988G>A / -1426C>T … show all	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*92	Not Available	1995delC	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*100	Not Available	-1426C>T / -1235A>G … show all	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*101	Not Available	-1426C>T / -1235A>G … show all	Effect Inferred	Poor drug metabolizer.	Details

Interactions

Drug Interactions

Drug	Interaction	Drug group
1,10-Phenanthroline	The serum concentration of Protriptyline can be increased when it is combined with 1,10-Phenanthroline.	Experimental
2,5-Dimethoxy-4-ethylamphetamine	Protriptyline may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.	Experimental, Illicit
3,4-Dichloroisocoumarin	The serum concentration of Protriptyline can be increased when it is combined with 3,4-Dichloroisocoumarin.	Experimental
3,4-Methylenedioxyamphetamine	Protriptyline may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.	Experimental, Illicit
3,4-Methylenedioxymethamphetamine	Protriptyline may increase the stimulatory activities of 3,4-Methylenedioxymethamphetamine.	Experimental, Illicit
4-(2-Aminoethyl)Benzenesulfonyl Fluoride	The serum concentration of Protriptyline can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.	Experimental
4-Bromo-2,5-dimethoxyamphetamine	Protriptyline may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.	Experimental, Illicit
4-Methoxyamphetamine	Protriptyline may decrease the antihypertensive activities of 4-Methoxyamphetamine.	Experimental, Illicit
7-Nitroindazole	The risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Protriptyline.	Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Protriptyline.	Experimental
Abiraterone	The serum concentration of Protriptyline can be increased when it is combined with Abiraterone.	Approved
Acebutolol	The serum concentration of Acebutolol can be increased when it is combined with Protriptyline.	Approved
Acenocoumarol	Protriptyline may increase the anticoagulant activities of Acenocoumarol.	Approved
Acepromazine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Protriptyline.	Approved, Vet Approved
Aceprometazine	The risk or severity of adverse effects can be increased when Aceprometazine is combined with Protriptyline.	Approved
Acetaminophen	The serum concentration of Acetaminophen can be increased when it is combined with Protriptyline.	Approved
Acetophenazine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Acetophenazine.	Approved
Acetylsalicylic acid	The serum concentration of Acetylsalicylic acid can be increased when it is combined with Protriptyline.	Approved, Vet Approved
Adipiplon	The risk or severity of adverse effects can be increased when adipiplon is combined with Protriptyline.	Investigational
Afatinib	The serum concentration of Afatinib can be increased when it is combined with Protriptyline.	Approved
Agmatine	Protriptyline may decrease the antihypertensive activities of Agmatine.	Experimental, Investigational
Agomelatine	The risk or severity of adverse effects can be increased when Agomelatine is combined with Protriptyline.	Approved, Investigational
Aldosterone	The serum concentration of Aldosterone can be increased when it is combined with Protriptyline.	Experimental
Alfaxalone	The risk or severity of adverse effects can be increased when Alfaxalone is combined with Protriptyline.	Vet Approved
Alfentanil	The risk or severity of adverse effects can be increased when Alfentanil is combined with Protriptyline.	Approved, Illicit
Alitretinoin	The serum concentration of Alitretinoin can be increased when it is combined with Protriptyline.	Approved, Investigational
Allopregnanolone	The risk or severity of adverse effects can be increased when Protriptyline is combined with Sage 547.	Investigational
Almotriptan	The risk or severity of adverse effects can be increased when Protriptyline is combined with Almotriptan.	Approved, Investigational
Alogliptin	The serum concentration of Protriptyline can be increased when it is combined with Alogliptin.	Approved
Alpha-1-proteinase inhibitor	The serum concentration of Protriptyline can be increased when it is combined with Alpha-1-proteinase inhibitor.	Approved
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Protriptyline.	Experimental, Illicit
Alprazolam	The risk or severity of adverse effects can be increased when Alprazolam is combined with Protriptyline.	Approved, Illicit, Investigational
Altretamine	Altretamine may increase the orthostatic hypotensive activities of Protriptyline.	Approved
Ambrisentan	The serum concentration of Ambrisentan can be increased when it is combined with Protriptyline.	Approved, Investigational
Amiodarone	Protriptyline may increase the QTc-prolonging activities of Amiodarone.	Approved, Investigational
Amisulpride	The risk or severity of adverse effects can be increased when Amisulpride is combined with Protriptyline.	Approved, Investigational
Amitriptyline	The risk or severity of adverse effects can be increased when Amitriptyline is combined with Protriptyline.	Approved
Amobarbital	The metabolism of Protriptyline can be increased when combined with Amobarbital.	Approved, Illicit
Amoxapine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Amoxapine.	Approved
Amperozide	The risk or severity of adverse effects can be increased when Amperozide is combined with Protriptyline.	Experimental
Amphetamine	Protriptyline may increase the stimulatory activities of Amphetamine.	Approved, Illicit
Amprenavir	The serum concentration of Protriptyline can be increased when it is combined with Amprenavir.	Approved
Anagrelide	Protriptyline may increase the QTc-prolonging activities of Anagrelide.	Approved
Antithrombin III human	The serum concentration of Protriptyline can be increased when it is combined with Antithrombin III human.	Approved
Apixaban	The serum concentration of Protriptyline can be increased when it is combined with Apixaban.	Approved
Apomorphine	Protriptyline may decrease the antihypertensive activities of Apomorphine.	Approved, Investigational
Apraclonidine	Protriptyline may decrease the antihypertensive activities of Apraclonidine.	Approved
Aprotinin	The serum concentration of Protriptyline can be increased when it is combined with Aprotinin.	Approved, Withdrawn
Arbutamine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Arbutamine.	Approved
Arformoterol	The risk or severity of adverse effects can be increased when Protriptyline is combined with Arformoterol.	Approved, Investigational
Argatroban	The serum concentration of Protriptyline can be increased when it is combined with Argatroban.	Approved, Investigational
Aripiprazole	The risk or severity of adverse effects can be increased when Aripiprazole is combined with Protriptyline.	Approved, Investigational
Arsenic trioxide	Protriptyline may increase the QTc-prolonging activities of Arsenic trioxide.	Approved, Investigational
Artemether	Protriptyline may increase the QTc-prolonging activities of Artemether.	Approved
Articaine	The risk or severity of adverse effects can be increased when Articaine is combined with Protriptyline.	Approved
Asenapine	Protriptyline may increase the QTc-prolonging activities of Asenapine.	Approved
Asunaprevir	The serum concentration of Protriptyline can be increased when it is combined with Asunaprevir.	Approved, Investigational
Atazanavir	The serum concentration of Protriptyline can be increased when it is combined with Atazanavir.	Approved, Investigational
Atenolol	The serum concentration of Atenolol can be increased when it is combined with Protriptyline.	Approved
Atomoxetine	The metabolism of Protriptyline can be decreased when combined with Atomoxetine.	Approved
Axitinib	The serum concentration of Axitinib can be increased when it is combined with Protriptyline.	Approved, Investigational
Azaperone	The risk or severity of adverse effects can be increased when Azaperone is combined with Protriptyline.	Vet Approved
Azelastine	Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.	Approved
Azelastine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Azelastine.	Approved
Azithromycin	Protriptyline may increase the QTc-prolonging activities of Azithromycin.	Approved
Baclofen	The risk or severity of adverse effects can be increased when Baclofen is combined with Protriptyline.	Approved
Bambuterol	The risk or severity of adverse effects can be increased when Protriptyline is combined with Bambuterol.	Approved
Barbexaclone	The metabolism of Protriptyline can be increased when combined with Barbexaclone.	Experimental
Barbital	The metabolism of Protriptyline can be increased when combined with Barbital.	Illicit
Batimastat	The serum concentration of Protriptyline can be increased when it is combined with Batimastat.	Experimental
Bedaquiline	Protriptyline may increase the QTc-prolonging activities of Bedaquiline.	Approved
Benazepril	The serum concentration of Protriptyline can be increased when it is combined with Benazepril.	Approved, Investigational
Benmoxin	Benmoxin may increase the serotonergic activities of Protriptyline.	Withdrawn
Benperidol	The risk or severity of adverse effects can be increased when Protriptyline is combined with Benperidol.	Investigational
Benzamidine	The serum concentration of Protriptyline can be increased when it is combined with Benzamidine.	Experimental
Benzocaine	The risk or severity of adverse effects can be increased when Benzocaine is combined with Protriptyline.	Approved
Benzphetamine	Protriptyline may decrease the antihypertensive activities of Benzphetamine.	Approved, Illicit
Benzyl alcohol	The risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Protriptyline.	Approved
Betamethasone	The serum concentration of Betamethasone can be increased when it is combined with Protriptyline.	Approved, Vet Approved
Betaxolol	The metabolism of Protriptyline can be decreased when combined with Betaxolol.	Approved
Bethanidine	Protriptyline may decrease the antihypertensive activities of Bethanidine.	Approved
Bifeprunox	The risk or severity of adverse effects can be increased when Protriptyline is combined with Bifeprunox.	Investigational
Bivalirudin	The serum concentration of Protriptyline can be increased when it is combined with Bivalirudin.	Approved, Investigational
Boceprevir	The serum concentration of Protriptyline can be increased when it is combined with Boceprevir.	Withdrawn
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Protriptyline.	Approved
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be increased when it is combined with Protriptyline.	Approved
Brexpiprazole	The risk or severity of adverse effects can be increased when Protriptyline is combined with Brexpiprazole.	Approved
Brimonidine	Protriptyline may decrease the antihypertensive activities of Brimonidine.	Approved
Brimonidine	The therapeutic efficacy of Brimonidine can be decreased when used in combination with Protriptyline.	Approved
Brimonidine	Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.	Approved
Bromazepam	The risk or severity of adverse effects can be increased when Bromazepam is combined with Protriptyline.	Approved, Illicit
Bromocriptine	Protriptyline may decrease the antihypertensive activities of Bromocriptine.	Approved, Investigational
Bromperidol	The risk or severity of adverse effects can be increased when Protriptyline is combined with Bromperidol.	Investigational
Brompheniramine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Brompheniramine.	Approved
Brotizolam	The risk or severity of adverse effects can be increased when Brotizolam is combined with Protriptyline.	Approved, Withdrawn
Bupivacaine	The risk or severity of adverse effects can be increased when Bupivacaine is combined with Protriptyline.	Approved, Investigational
Buprenorphine	Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Bupropion	The metabolism of Protriptyline can be decreased when combined with Bupropion.	Approved
Buspirone	The risk or severity of adverse effects can be increased when Protriptyline is combined with Buspirone.	Approved, Investigational
Butabarbital	The risk or severity of adverse effects can be increased when Butabarbital is combined with Protriptyline.	Approved, Illicit
Butacaine	The risk or severity of adverse effects can be increased when Butacaine is combined with Protriptyline.	Vet Approved
Butalbital	The risk or severity of adverse effects can be increased when Butalbital is combined with Protriptyline.	Approved, Illicit
Butamben	The risk or severity of adverse effects can be increased when Butamben is combined with Protriptyline.	Approved
Butethal	The risk or severity of adverse effects can be increased when Butethal is combined with Protriptyline.	Approved, Illicit
Butorphanol	The risk or severity of adverse effects can be increased when Butorphanol is combined with Protriptyline.	Approved, Illicit, Vet Approved
Cabazitaxel	The serum concentration of Cabazitaxel can be increased when it is combined with Protriptyline.	Approved
Cabergoline	The risk or severity of adverse effects can be increased when Cabergoline is combined with Protriptyline.	Approved
Caffeine	The serum concentration of Caffeine can be increased when it is combined with Protriptyline.	Approved
Camptothecin	The serum concentration of Camptothecin can be increased when it is combined with Protriptyline.	Experimental
Canagliflozin	The serum concentration of Canagliflozin can be increased when it is combined with Protriptyline.	Approved
Candoxatril	The serum concentration of Protriptyline can be increased when it is combined with Candoxatril.	Experimental
Candoxatrilat	The serum concentration of Protriptyline can be increased when it is combined with Candoxatrilat.	Experimental
Captopril	The serum concentration of Protriptyline can be increased when it is combined with Captopril.	Approved
Carbamazepine	The metabolism of Protriptyline can be increased when combined with Carbamazepine.	Approved, Investigational
Carbinoxamine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Carbinoxamine.	Approved
Carfentanil	The risk or severity of adverse effects can be increased when Carfentanil is combined with Protriptyline.	Illicit, Vet Approved
Carfilzomib	The serum concentration of Carfilzomib can be increased when it is combined with Protriptyline.	Approved
Cariprazine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Cariprazine.	Approved
Carisoprodol	The risk or severity of adverse effects can be increased when Protriptyline is combined with Carisoprodol.	Approved
Caroxazone	Caroxazone may increase the serotonergic activities of Protriptyline.	Withdrawn
Celecoxib	The metabolism of Protriptyline can be decreased when combined with Celecoxib.	Approved, Investigational
Celiprolol	The risk or severity of adverse effects can be increased when Protriptyline is combined with Celiprolol.	Approved, Investigational
Ceritinib	Protriptyline may increase the QTc-prolonging activities of Ceritinib.	Approved
Cerivastatin	The serum concentration of Cerivastatin can be increased when it is combined with Protriptyline.	Withdrawn
Cetirizine	The risk or severity of adverse effects can be increased when Cetirizine is combined with Protriptyline.	Approved
Chloral hydrate	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Protriptyline.	Approved, Illicit, Vet Approved
Chlordiazepoxide	The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Protriptyline.	Approved, Illicit
Chlormezanone	The risk or severity of adverse effects can be increased when Chlormezanone is combined with Protriptyline.	Approved, Withdrawn
Chloroprocaine	The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Protriptyline.	Approved
Chloroquine	Protriptyline may increase the QTc-prolonging activities of Chloroquine.	Approved, Vet Approved
Chlorphenamine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Chlorphenamine.	Approved
Chlorphentermine	Protriptyline may increase the stimulatory activities of Chlorphentermine.	Illicit, Withdrawn
Chlorpromazine	Protriptyline may increase the QTc-prolonging activities of Chlorpromazine.	Approved, Vet Approved
Chlorprothixene	The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Protriptyline.	Approved, Withdrawn
Chlorzoxazone	The risk or severity of adverse effects can be increased when Protriptyline is combined with Chlorzoxazone.	Approved
Cholecalciferol	The metabolism of Protriptyline can be decreased when combined with Cholecalciferol.	Approved, Nutraceutical
Chymostatin	The serum concentration of Protriptyline can be increased when it is combined with Chymostatin.	Experimental
Cilastatin	The serum concentration of Protriptyline can be increased when it is combined with Cilastatin.	Approved
Cilazapril	The serum concentration of Protriptyline can be increased when it is combined with Cilazapril.	Approved
Cimetidine	The metabolism of Protriptyline can be decreased when combined with Cimetidine.	Approved
Cinacalcet	The serum concentration of Protriptyline can be increased when it is combined with Cinacalcet.	Approved
Cinchocaine	The risk or severity of adverse effects can be increased when Cinchocaine is combined with Protriptyline.	Approved, Vet Approved
Ciprofloxacin	Protriptyline may increase the QTc-prolonging activities of Ciprofloxacin.	Approved, Investigational
Cirazoline	Protriptyline may increase the vasopressor activities of Cirazoline.	Experimental
Cisapride	Protriptyline may increase the arrhythmogenic activities of Cisapride.	Approved, Investigational, Withdrawn
Cisplatin	The serum concentration of Cisplatin can be increased when it is combined with Protriptyline.	Approved
Citalopram	The risk or severity of adverse effects can be increased when Protriptyline is combined with Citalopram.	Approved
Clarithromycin	Protriptyline may increase the QTc-prolonging activities of Clarithromycin.	Approved
Clemastine	The metabolism of Protriptyline can be decreased when combined with Clemastine.	Approved
Clenbuterol	The risk or severity of adverse effects can be increased when Protriptyline is combined with Clenbuterol.	Approved, Vet Approved
Clidinium	The risk or severity of adverse effects can be increased when Protriptyline is combined with Clidinium.	Approved
Clobazam	The serum concentration of Clobazam can be increased when it is combined with Protriptyline.	Approved, Illicit
clomethiazole	The risk or severity of adverse effects can be increased when clomethiazole is combined with Protriptyline.	Investigational
Clomifene	The serum concentration of Clomifene can be increased when it is combined with Protriptyline.	Approved, Investigational
Clomipramine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Clomipramine.	Approved, Vet Approved
Clonazepam	The risk or severity of adverse effects can be increased when Protriptyline is combined with Clonazepam.	Approved, Illicit
Clonidine	Protriptyline may decrease the antihypertensive activities of Clonidine.	Approved
Clopidogrel	The serum concentration of Clopidogrel can be increased when it is combined with Protriptyline.	Approved, Nutraceutical
Clorazepate	The risk or severity of adverse effects can be increased when Clorazepate is combined with Protriptyline.	Approved, Illicit
Clotrimazole	The metabolism of Protriptyline can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	Protriptyline may increase the QTc-prolonging activities of Clozapine.	Approved
Cobicistat	The serum concentration of Protriptyline can be increased when it is combined with Cobicistat.	Approved
Cobimetinib	The serum concentration of Cobimetinib can be increased when it is combined with Protriptyline.	Approved
Cocaine	The metabolism of Protriptyline can be decreased when combined with Cocaine.	Approved, Illicit
Codeine	The risk or severity of adverse effects can be increased when Codeine is combined with Protriptyline.	Approved, Illicit
Colchicine	The serum concentration of Colchicine can be increased when it is combined with Protriptyline.	Approved
Conjugated estrogens	The serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Protriptyline.	Approved
Crizotinib	Protriptyline may increase the QTc-prolonging activities of Crizotinib.	Approved
Cyamemazine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Cyamemazine.	Approved
Cyclizine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Cyclizine.	Approved
Cyclobenzaprine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Cyclobenzaprine.	Approved
Cyclosporine	The serum concentration of Cyclosporine can be increased when it is combined with Protriptyline.	Approved, Investigational, Vet Approved
Cyproheptadine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Cyproheptadine.	Approved
Dabigatran etexilate	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Protriptyline.	Approved
Dabrafenib	The serum concentration of Dabrafenib can be increased when it is combined with Protriptyline.	Approved
Dactinomycin	The serum concentration of Dactinomycin can be increased when it is combined with Protriptyline.	Approved
Dantrolene	The risk or severity of adverse effects can be increased when Protriptyline is combined with Dantrolene.	Approved
Dapagliflozin	The serum concentration of Dapagliflozin can be increased when it is combined with Protriptyline.	Approved
Dapiprazole	The risk or severity of adverse effects can be increased when Dapiprazole is combined with Protriptyline.	Approved
Dapoxetine	The risk or severity of adverse effects can be increased when Dapoxetine is combined with Protriptyline.	Investigational
Darexaban	The serum concentration of Protriptyline can be increased when it is combined with Ym150.	Investigational
Darifenacin	The metabolism of Protriptyline can be decreased when combined with Darifenacin.	Approved, Investigational
Darunavir	The serum concentration of Protriptyline can be increased when it is combined with Darunavir.	Approved
Dasatinib	The serum concentration of Dasatinib can be increased when it is combined with Protriptyline.	Approved, Investigational
Daunorubicin	The serum concentration of Daunorubicin can be increased when it is combined with Protriptyline.	Approved
Debrisoquin	The serum concentration of Debrisoquin can be increased when it is combined with Protriptyline.	Approved
Delavirdine	The metabolism of Protriptyline can be decreased when combined with Delavirdine.	Approved
Deramciclane	The risk or severity of adverse effects can be increased when deramciclane is combined with Protriptyline.	Investigational
Desflurane	The risk or severity of adverse effects can be increased when Desflurane is combined with Protriptyline.	Approved
Desipramine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Desipramine.	Approved
Desloratadine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Desloratadine.	Approved, Investigational
Desmopressin	The risk or severity of adverse effects can be increased when Protriptyline is combined with Desmopressin.	Approved
Desvenlafaxine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Desvenlafaxine.	Approved
Detomidine	The risk or severity of adverse effects can be increased when Detomidine is combined with Protriptyline.	Vet Approved
Dexamethasone	The serum concentration of Dexamethasone can be increased when it is combined with Protriptyline.	Approved, Investigational, Vet Approved
Dexbrompheniramine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Dexbrompheniramine.	Approved
Dexmedetomidine	Protriptyline may decrease the antihypertensive activities of Dexmedetomidine.	Approved, Vet Approved
Dexmethylphenidate	The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Protriptyline.	Approved
Dextroamphetamine	Protriptyline may increase the stimulatory activities of Dextroamphetamine.	Approved, Illicit
Dextromethorphan	The risk or severity of adverse effects can be increased when Protriptyline is combined with Dextromethorphan.	Approved
Dextromoramide	The risk or severity of adverse effects can be increased when Dextromoramide is combined with Protriptyline.	Experimental, Illicit
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Protriptyline.	Approved, Illicit, Withdrawn
Dezocine	The risk or severity of adverse effects can be increased when Dezocine is combined with Protriptyline.	Approved
Diazepam	The serum concentration of Diazepam can be increased when it is combined with Protriptyline.	Approved, Illicit, Vet Approved
Dicoumarol	Protriptyline may increase the anticoagulant activities of Dicoumarol.	Approved
Diethylpropion	Protriptyline may increase the stimulatory activities of Diethylpropion.	Approved, Illicit
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be increased when it is combined with Protriptyline.	Approved
Difenoxin	The risk or severity of adverse effects can be increased when Protriptyline is combined with Difenoxin.	Approved, Illicit
Digitoxin	The serum concentration of Digitoxin can be increased when it is combined with Protriptyline.	Approved
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Protriptyline.	Approved
Dihydrocodeine	The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Protriptyline.	Approved, Illicit
Dihydroergotamine	Protriptyline may decrease the antihypertensive activities of Dihydroergotamine.	Approved
Dihydroetorphine	The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Protriptyline.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Protriptyline.	Experimental, Illicit
Dihydrotestosterone	The serum concentration of Dihydrotestosterone can be increased when it is combined with Protriptyline.	Illicit
Diltiazem	The serum concentration of Diltiazem can be increased when it is combined with Protriptyline.	Approved
Dimenhydrinate	The risk or severity of adverse effects can be increased when Protriptyline is combined with Dimenhydrinate.	Approved
Diphenhydramine	The metabolism of Protriptyline can be decreased when combined with Diphenhydramine.	Approved
Diphenoxylate	The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Protriptyline.	Approved, Illicit
Dipivefrin	Protriptyline may decrease the antihypertensive activities of Dipivefrin.	Approved
Dipyridamole	The serum concentration of Dipyridamole can be increased when it is combined with Protriptyline.	Approved
Disopyramide	Protriptyline may increase the QTc-prolonging activities of Disopyramide.	Approved
Dobutamine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Dobutamine.	Approved
Docetaxel	The serum concentration of Docetaxel can be increased when it is combined with Protriptyline.	Approved, Investigational
Dofetilide	Protriptyline may increase the QTc-prolonging activities of Dofetilide.	Approved
Dolasetron	Protriptyline may increase the QTc-prolonging activities of Dolasetron.	Approved
Domperidone	Protriptyline may increase the QTc-prolonging activities of Domperidone.	Approved, Investigational, Vet Approved
Doramectin	The risk or severity of adverse effects can be increased when Doramectin is combined with Protriptyline.	Vet Approved
Doxepin	The risk or severity of adverse effects can be increased when Protriptyline is combined with Doxepin.	Approved
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Protriptyline.	Approved, Investigational
Doxylamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.	Approved, Vet Approved
DPDPE	The risk or severity of adverse effects can be increased when DPDPE is combined with Protriptyline.	Investigational
Dronabinol	Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.	Approved, Illicit
Dronedarone	Protriptyline may increase the QTc-prolonging activities of Dronedarone.	Approved
Droperidol	Droperidol may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.	Approved, Vet Approved
Drotebanol	The risk or severity of adverse effects can be increased when Drotebanol is combined with Protriptyline.	Experimental, Illicit
Droxidopa	Protriptyline may decrease the antihypertensive activities of Droxidopa.	Approved, Investigational
Duloxetine	Duloxetine may increase the serotonergic activities of Protriptyline.	Approved
Dyclonine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Protriptyline.	Approved
Ecabet	The serum concentration of Protriptyline can be increased when it is combined with Ecabet.	Approved, Investigational
Ecgonine	The risk or severity of adverse effects can be increased when Ecgonine is combined with Protriptyline.	Experimental, Illicit
Ecopipam	The risk or severity of adverse effects can be increased when Protriptyline is combined with Ecopipam.	Investigational
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Protriptyline.	Approved
Efavirenz	The risk or severity of adverse effects can be increased when Protriptyline is combined with Efavirenz.	Approved, Investigational
Elafin	The serum concentration of Protriptyline can be increased when it is combined with Elafin.	Investigational
Eletriptan	The risk or severity of adverse effects can be increased when Eletriptan is combined with Protriptyline.	Approved, Investigational
Eliglustat	Protriptyline may increase the QTc-prolonging activities of Eliglustat.	Approved
Eltanolone	The risk or severity of adverse effects can be increased when Protriptyline is combined with Pregnanolone.	Investigational
Enalapril	The serum concentration of Protriptyline can be increased when it is combined with Enalapril.	Approved, Vet Approved
Enalaprilat	The serum concentration of Protriptyline can be increased when it is combined with Enalaprilat.	Approved
Enalkiren	The serum concentration of Protriptyline can be increased when it is combined with Enalkiren.	Experimental
Enflurane	The risk or severity of adverse effects can be increased when Enflurane is combined with Protriptyline.	Approved, Vet Approved
Entacapone	The risk or severity of adverse effects can be increased when Protriptyline is combined with Entacapone.	Approved, Investigational
Ephedra	Protriptyline may decrease the antihypertensive activities of Ephedra.	Approved, Nutraceutical, Withdrawn
Epinastine	The serum concentration of Epinastine can be increased when it is combined with Protriptyline.	Approved, Investigational
Epinephrine	Protriptyline may decrease the antihypertensive activities of Epinephrine.	Approved, Vet Approved
Ergoloid mesylate	The risk or severity of adverse effects can be increased when Protriptyline is combined with Ergoloid mesylate.	Approved
Ergonovine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Ergonovine.	Approved
Ergotamine	Protriptyline may decrease the antihypertensive activities of Ergotamine.	Approved
Erlotinib	The serum concentration of Erlotinib can be increased when it is combined with Protriptyline.	Approved, Investigational
Erythromycin	Protriptyline may increase the QTc-prolonging activities of Erythromycin.	Approved, Vet Approved
Escitalopram	The risk or severity of adverse effects can be increased when Protriptyline is combined with Escitalopram.	Approved, Investigational
Estazolam	The risk or severity of adverse effects can be increased when Estazolam is combined with Protriptyline.	Approved, Illicit
Estradiol	The serum concentration of Estradiol can be increased when it is combined with Protriptyline.	Approved, Investigational, Vet Approved
Estriol	The serum concentration of Estriol can be increased when it is combined with Protriptyline.	Approved, Vet Approved
Estrone	The serum concentration of Estrone can be increased when it is combined with Protriptyline.	Approved
Eszopiclone	The risk or severity of adverse effects can be increased when Eszopiclone is combined with Protriptyline.	Approved
Ethanol	Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.	Approved
Ethchlorvynol	The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Protriptyline.	Approved, Illicit, Withdrawn
Ethinyl Estradiol	The serum concentration of Ethinyl Estradiol can be increased when it is combined with Protriptyline.	Approved
Ethosuximide	The risk or severity of adverse effects can be increased when Protriptyline is combined with Ethosuximide.	Approved
Ethotoin	The risk or severity of adverse effects can be increased when Protriptyline is combined with Ethotoin.	Approved
Ethyl biscoumacetate	Protriptyline may increase the anticoagulant activities of Ethyl biscoumacetate.	Withdrawn
Ethyl carbamate	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Protriptyline.	Withdrawn
Ethyl loflazepate	The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Protriptyline.	Approved, Illicit
Ethylmorphine	The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Protriptyline.	Approved, Illicit
Etidocaine	The risk or severity of adverse effects can be increased when Etidocaine is combined with Protriptyline.	Approved
Etifoxine	The risk or severity of adverse effects can be increased when Etifoxine is combined with Protriptyline.	Withdrawn
Etizolam	The risk or severity of adverse effects can be increased when Etizolam is combined with Protriptyline.	Approved
Etomidate	Protriptyline may decrease the antihypertensive activities of Etomidate.	Approved
Etoperidone	The risk or severity of adverse effects can be increased when Protriptyline is combined with Etoperidone.	Approved
Etoposide	The serum concentration of Etoposide can be increased when it is combined with Protriptyline.	Approved
Etorphine	The risk or severity of adverse effects can be increased when Etorphine is combined with Protriptyline.	Illicit, Vet Approved
Everolimus	The serum concentration of Everolimus can be increased when it is combined with Protriptyline.	Approved
Ezetimibe	The serum concentration of Ezetimibe can be increased when it is combined with Protriptyline.	Approved
Ezogabine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Ezogabine.	Approved
Faldaprevir	The serum concentration of Protriptyline can be increased when it is combined with Bi201335.	Investigational
Felbamate	The risk or severity of adverse effects can be increased when Protriptyline is combined with Felbamate.	Approved
Fencamfamine	The risk or severity of adverse effects can be increased when Fencamfamine is combined with Protriptyline.	Approved, Illicit, Withdrawn
Fenoterol	The risk or severity of adverse effects can be increased when Protriptyline is combined with Fenoterol.	Approved
Fentanyl	The risk or severity of adverse effects can be increased when Protriptyline is combined with Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Fesoterodine	The serum concentration of Fesoterodine can be increased when it is combined with Protriptyline.	Approved
Fexofenadine	The serum concentration of Fexofenadine can be increased when it is combined with Protriptyline.	Approved
Fidaxomicin	The serum concentration of Fidaxomicin can be increased when it is combined with Protriptyline.	Approved
Flecainide	Protriptyline may increase the QTc-prolonging activities of Flecainide.	Approved, Withdrawn
Flibanserin	The risk or severity of adverse effects can be increased when Protriptyline is combined with Flibanserin.	Approved
Fludiazepam	The risk or severity of adverse effects can be increased when Fludiazepam is combined with Protriptyline.	Approved, Illicit
Fluindione	Protriptyline may increase the anticoagulant activities of Fluindione.	Investigational
Flunarizine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Flunarizine.	Approved
Flunitrazepam	The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Protriptyline.	Approved, Illicit
Fluoxetine	The risk or severity of adverse effects can be increased when Fluoxetine is combined with Protriptyline.	Approved, Vet Approved
Flupentixol	Protriptyline may increase the QTc-prolonging activities of Flupentixol.	Approved, Withdrawn
Fluphenazine	The risk or severity of adverse effects can be increased when Fluphenazine is combined with Protriptyline.	Approved
Flurazepam	The risk or severity of adverse effects can be increased when Flurazepam is combined with Protriptyline.	Approved, Illicit
Fluspirilene	The risk or severity of adverse effects can be increased when Fluspirilene is combined with Protriptyline.	Approved
Fluticasone furoate	The serum concentration of Fluticasone furoate can be increased when it is combined with Protriptyline.	Approved
Fluticasone propionate	The risk or severity of adverse effects can be increased when Protriptyline is combined with Fluticasone Propionate.	Approved
Fluvoxamine	The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Protriptyline.	Approved, Investigational
Formoterol	The risk or severity of adverse effects can be increased when Protriptyline is combined with Formoterol.	Approved, Investigational
Fosamprenavir	The serum concentration of Protriptyline can be increased when it is combined with Fosamprenavir.	Approved
Fosinopril	The serum concentration of Protriptyline can be increased when it is combined with Fosinopril.	Approved
Fosphenytoin	The risk or severity of adverse effects can be increased when Protriptyline is combined with Fosphenytoin.	Approved
Fospropofol	The risk or severity of adverse effects can be increased when Fospropofol is combined with Protriptyline.	Approved, Illicit
Frovatriptan	The risk or severity of adverse effects can be increased when Protriptyline is combined with Frovatriptan.	Approved, Investigational
Furazolidone	Furazolidone may increase the serotonergic activities of Protriptyline.	Approved, Vet Approved
Gabapentin	The risk or severity of adverse effects can be increased when Gabapentin is combined with Protriptyline.	Approved, Investigational
Gabapentin Enacarbil	The risk or severity of adverse effects can be increased when Protriptyline is combined with gabapentin enacarbil.	Approved
Gabexate	The serum concentration of Protriptyline can be increased when it is combined with Gabexate.	Investigational
Gadobenic acid	Protriptyline may increase the QTc-prolonging activities of Gadobenic acid.	Approved
Gamma Hydroxybutyric Acid	The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Protriptyline.	Approved, Illicit
Gefitinib	The serum concentration of Gefitinib can be increased when it is combined with Protriptyline.	Approved, Investigational
Geldanamycin	The serum concentration of Protriptyline can be increased when it is combined with Geldanamycin.	Experimental
Gemcitabine	The serum concentration of Gemcitabine can be increased when it is combined with Protriptyline.	Approved
Gemifloxacin	Protriptyline may increase the QTc-prolonging activities of Gemifloxacin.	Approved, Investigational
Gepirone	The risk or severity of adverse effects can be increased when Protriptyline is combined with Gepirone.	Investigational
Glutethimide	The risk or severity of adverse effects can be increased when Glutethimide is combined with Protriptyline.	Approved, Illicit
GM6001	The serum concentration of Protriptyline can be increased when it is combined with GM6001.	Experimental
Goserelin	Protriptyline may increase the QTc-prolonging activities of Goserelin.	Approved
Granisetron	Protriptyline may increase the QTc-prolonging activities of Granisetron.	Approved, Investigational
Grazoprevir	The serum concentration of Grazoprevir can be increased when it is combined with Protriptyline.	Approved
Grepafloxacin	The serum concentration of Grepafloxacin can be increased when it is combined with Protriptyline.	Withdrawn
Guanabenz	Protriptyline may decrease the antihypertensive activities of Guanabenz.	Approved
Guanfacine	Protriptyline may decrease the antihypertensive activities of Guanfacine.	Approved, Investigational
Halazepam	The risk or severity of adverse effects can be increased when Halazepam is combined with Protriptyline.	Approved, Illicit, Withdrawn
Haloperidol	Protriptyline may increase the QTc-prolonging activities of Haloperidol.	Approved
Halothane	The risk or severity of adverse effects can be increased when Halothane is combined with Protriptyline.	Approved, Vet Approved
Heroin	The risk or severity of adverse effects can be increased when Heroin is combined with Protriptyline.	Approved, Illicit
Hexobarbital	The metabolism of Protriptyline can be increased when combined with Hexobarbital.	Approved
Hydracarbazine	Hydracarbazine may increase the serotonergic activities of Protriptyline.	Experimental
Hydrocodone	Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.	Approved, Illicit
Hydrocortisone	The serum concentration of Hydrocortisone can be increased when it is combined with Protriptyline.	Approved, Vet Approved
Hydromorphone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Protriptyline.	Approved, Illicit
Hydroxyamphetamine	Protriptyline may increase the stimulatory activities of Hydroxyamphetamine hydrobromide.	Approved
Hydroxyzine	Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.	Approved
Ibuprofen	The serum concentration of Ibuprofen can be increased when it is combined with Protriptyline.	Approved
Ibutilide	Protriptyline may increase the QTc-prolonging activities of Ibutilide.	Approved
Idelalisib	The serum concentration of Idelalisib can be increased when it is combined with Protriptyline.	Approved
Idraparinux	The serum concentration of Protriptyline can be increased when it is combined with idraparinux.	Investigational
Iloperidone	Protriptyline may increase the QTc-prolonging activities of Iloperidone.	Approved
Imatinib	The serum concentration of Imatinib can be increased when it is combined with Protriptyline.	Approved
Imidapril	The serum concentration of Protriptyline can be increased when it is combined with Imidapril.	Investigational
Imipramine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Imipramine.	Approved
Indacaterol	The serum concentration of Indacaterol can be increased when it is combined with Protriptyline.	Approved
Indalpine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Indalpine.	Investigational, Withdrawn
Indinavir	The serum concentration of Protriptyline can be increased when it is combined with Indinavir.	Approved
Indomethacin	The serum concentration of Indomethacin can be increased when it is combined with Protriptyline.	Approved, Investigational
Iobenguane	The therapeutic efficacy of Iobenguane can be decreased when used in combination with Protriptyline.	Approved
Iproclozide	Iproclozide may increase the serotonergic activities of Protriptyline.	Withdrawn
Iproniazid	Iproniazid may increase the serotonergic activities of Protriptyline.	Withdrawn
Irinotecan	The serum concentration of Irinotecan can be increased when it is combined with Protriptyline.	Approved, Investigational
Isocarboxazid	Isocarboxazid may increase the serotonergic activities of Protriptyline.	Approved
Isoetarine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Isoetarine.	Approved
Isoflurane	The risk or severity of adverse effects can be increased when Isoflurane is combined with Protriptyline.	Approved, Vet Approved
Isoflurophate	The serum concentration of Protriptyline can be increased when it is combined with Isoflurophate.	Approved, Withdrawn
Isoniazid	The metabolism of Protriptyline can be decreased when combined with Isoniazid.	Approved
Isoprenaline	The risk or severity of adverse effects can be increased when Protriptyline is combined with Isoprenaline.	Approved
Ivermectin	The serum concentration of Ivermectin can be increased when it is combined with Protriptyline.	Approved, Vet Approved
Ixazomib	The serum concentration of Protriptyline can be increased when it is combined with Ixazomib.	Approved
Ketamine	The risk or severity of adverse effects can be increased when Ketamine is combined with Protriptyline.	Approved, Vet Approved
Ketazolam	The serum concentration of Ketazolam can be increased when it is combined with Protriptyline.	Approved
Ketobemidone	The risk or severity of adverse effects can be increased when Ketobemidone is combined with Protriptyline.	Approved
Ketoconazole	The serum concentration of Ketoconazole can be increased when it is combined with Protriptyline.	Approved, Investigational
Lamivudine	The serum concentration of Lamivudine can be increased when it is combined with Protriptyline.	Approved, Investigational
Lamotrigine	The serum concentration of Lamotrigine can be increased when it is combined with Protriptyline.	Approved, Investigational
Lansoprazole	The serum concentration of Lansoprazole can be increased when it is combined with Protriptyline.	Approved, Investigational
Ledipasvir	The serum concentration of Ledipasvir can be increased when it is combined with Protriptyline.	Approved
Lenalidomide	The serum concentration of Lenalidomide can be increased when it is combined with Protriptyline.	Approved
Lenvatinib	Protriptyline may increase the QTc-prolonging activities of Lenvatinib.	Approved
Lepirudin	The serum concentration of Protriptyline can be increased when it is combined with Lepirudin.	Approved
Leuprolide	Protriptyline may increase the QTc-prolonging activities of Leuprolide.	Approved, Investigational
Levetiracetam	The serum concentration of Levetiracetam can be increased when it is combined with Protriptyline.	Approved, Investigational
Levobupivacaine	The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Protriptyline.	Approved
Levocabastine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Levocabastine.	Approved
Levocetirizine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Levocetirizine.	Approved
Levodopa	The risk or severity of adverse effects can be increased when Protriptyline is combined with Levodopa.	Approved
Levofloxacin	Protriptyline may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Levomethadyl Acetate	The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Protriptyline.	Approved
Levomilnacipran	The risk or severity of adverse effects can be increased when Protriptyline is combined with Levomilnacipran.	Approved
Levorphanol	The risk or severity of adverse effects can be increased when Levorphanol is combined with Protriptyline.	Approved
Levothyroxine	Levothyroxine may increase the arrhythmogenic activities of Protriptyline.	Approved
Lidocaine	The risk or severity of adverse effects can be increased when Lidocaine is combined with Protriptyline.	Approved, Vet Approved
Linagliptin	The serum concentration of Protriptyline can be increased when it is combined with Linagliptin.	Approved
Linezolid	Linezolid may increase the serotonergic activities of Protriptyline.	Approved, Investigational
Liothyronine	Liothyronine may increase the arrhythmogenic activities of Protriptyline.	Approved, Vet Approved
Liotrix	Liotrix may increase the arrhythmogenic activities of Protriptyline.	Approved
Lisdexamfetamine	Protriptyline may increase the stimulatory activities of Lisdexamfetamine.	Approved, Investigational
Lisinopril	The serum concentration of Protriptyline can be increased when it is combined with Lisinopril.	Approved, Investigational
Lithium	Lithium may increase the neurotoxic activities of Protriptyline.	Approved
Lofentanil	The risk or severity of adverse effects can be increased when Lofentanil is combined with Protriptyline.	Illicit
Lofexidine	Protriptyline may decrease the antihypertensive activities of Lofexidine.	Approved, Investigational
Loperamide	The serum concentration of Loperamide can be increased when it is combined with Protriptyline.	Approved
Lopinavir	Protriptyline may increase the QTc-prolonging activities of Lopinavir.	Approved
Loratadine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Loratadine.	Approved
Lorazepam	The risk or severity of adverse effects can be increased when Lorazepam is combined with Protriptyline.	Approved
Lorcaserin	The risk or severity of adverse effects can be increased when Protriptyline is combined with Lorcaserin.	Approved
Losartan	The serum concentration of Losartan can be increased when it is combined with Protriptyline.	Approved
Loxapine	The risk or severity of adverse effects can be increased when Loxapine is combined with Protriptyline.	Approved
Lumefantrine	Protriptyline may increase the QTc-prolonging activities of Lumefantrine.	Approved
Lurasidone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Protriptyline.	Approved
Magnesium Sulfate	Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.	Approved, Vet Approved
Mannitol	The serum concentration of Mannitol can be increased when it is combined with Protriptyline.	Approved, Investigational
Maprotiline	The risk or severity of adverse effects can be increased when Protriptyline is combined with Maprotiline.	Approved
Mebanazine	Mebanazine may increase the serotonergic activities of Protriptyline.	Withdrawn
Meclizine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Meclizine.	Approved
Medetomidine	The risk or severity of adverse effects can be increased when Medetomidine is combined with Protriptyline.	Vet Approved
Melatonin	The risk or severity of adverse effects can be increased when Melatonin is combined with Protriptyline.	Approved, Nutraceutical, Vet Approved
Melperone	The risk or severity of adverse effects can be increased when Melperone is combined with Protriptyline.	Approved
Mephedrone	Protriptyline may increase the stimulatory activities of Mephedrone.	Investigational
Mephentermine	Protriptyline may increase the vasopressor activities of Mephentermine.	Approved
Mepivacaine	The risk or severity of adverse effects can be increased when Mepivacaine is combined with Protriptyline.	Approved, Vet Approved
Meprobamate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Protriptyline.	Approved, Illicit
Mesoridazine	The risk or severity of adverse effects can be increased when Mesoridazine is combined with Protriptyline.	Approved
Metaraminol	Protriptyline may increase the vasopressor activities of Metaraminol.	Approved, Investigational
Metaxalone	The risk or severity of adverse effects can be increased when Protriptyline is combined with Metaxalone.	Approved
Methadone	The risk or severity of adverse effects can be increased when Methadone is combined with Protriptyline.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Protriptyline.	Approved, Illicit
Methamphetamine	Protriptyline may decrease the antihypertensive activities of Methamphetamine.	Approved, Illicit
Methapyrilene	The risk or severity of adverse effects can be increased when Methapyrilene is combined with Protriptyline.	Withdrawn
Methaqualone	The risk or severity of adverse effects can be increased when Methaqualone is combined with Protriptyline.	Illicit, Withdrawn
Methocarbamol	The risk or severity of adverse effects can be increased when Protriptyline is combined with Methocarbamol.	Approved, Vet Approved
Methohexital	The metabolism of Protriptyline can be increased when combined with Methohexital.	Approved
Methotrexate	The serum concentration of Methotrexate can be increased when it is combined with Protriptyline.	Approved
Methotrimeprazine	Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.	Approved
Methoxamine	Protriptyline may increase the vasopressor activities of Methoxamine.	Approved
Methoxyflurane	The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Protriptyline.	Approved, Vet Approved
Methsuximide	The risk or severity of adverse effects can be increased when Protriptyline is combined with Methsuximide.	Approved
Methylecgonine	The risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Protriptyline.	Experimental
Methylene blue	Protriptyline may increase the serotonergic activities of Methylene blue.	Investigational
Methylphenidate	The risk or severity of adverse effects can be increased when Methylphenidate is combined with Protriptyline.	Approved, Investigational
Methylphenobarbital	The metabolism of Protriptyline can be increased when combined with Methylphenobarbital.	Approved
Methylprednisolone	The serum concentration of Methylprednisolone can be increased when it is combined with Protriptyline.	Approved, Vet Approved
Metoclopramide	The risk or severity of adverse effects can be increased when Metoclopramide is combined with Protriptyline.	Approved, Investigational
Metoprolol	The serum concentration of Metoprolol can be increased when it is combined with Protriptyline.	Approved, Investigational
Metyrosine	Protriptyline may increase the sedative activities of Metyrosine.	Approved
Midazolam	The serum concentration of Midazolam can be increased when it is combined with Protriptyline.	Approved, Illicit
Midodrine	Protriptyline may increase the vasopressor activities of Midodrine.	Approved
Mifepristone	Mifepristone may increase the QTc-prolonging activities of Protriptyline.	Approved, Investigational
Milnacipran	The risk or severity of adverse effects can be increased when Protriptyline is combined with Milnacipran.	Approved
Minaprine	Minaprine may increase the serotonergic activities of Protriptyline.	Approved
Minocycline	Minocycline may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.	Approved, Investigational
Mirabegron	The serum concentration of Mirabegron can be increased when it is combined with Protriptyline.	Approved
Mirtazapine	Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.	Approved
Mitoxantrone	The serum concentration of Mitoxantrone can be increased when it is combined with Protriptyline.	Approved, Investigational
MMDA	Protriptyline may increase the stimulatory activities of MMDA.	Experimental, Illicit
Moclobemide	Moclobemide may increase the serotonergic activities of Protriptyline.	Approved
Moexipril	The serum concentration of Protriptyline can be increased when it is combined with Moexipril.	Approved
Molindone	The risk or severity of adverse effects can be increased when Molindone is combined with Protriptyline.	Approved
Morphine	The serum concentration of Morphine can be increased when it is combined with Protriptyline.	Approved, Investigational
Moxifloxacin	Protriptyline may increase the QTc-prolonging activities of Moxifloxacin.	Approved, Investigational
Moxonidine	The therapeutic efficacy of Moxonidine can be decreased when used in combination with Protriptyline.	Approved
Mycophenolate mofetil	The serum concentration of Mycophenolate mofetil can be increased when it is combined with Protriptyline.	Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline	The serum concentration of Protriptyline can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.	Experimental
Nabilone	Nabilone may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.	Approved, Investigational
Nadolol	The serum concentration of Nadolol can be increased when it is combined with Protriptyline.	Approved
Nafamostat	The serum concentration of Protriptyline can be increased when it is combined with Nafamostat.	Approved, Investigational
Nalbuphine	The risk or severity of adverse effects can be increased when Nalbuphine is combined with Protriptyline.	Approved
Naloxegol	The serum concentration of Naloxegol can be increased when it is combined with Protriptyline.	Approved
Naloxone	The serum concentration of Naloxone can be increased when it is combined with Protriptyline.	Approved, Vet Approved
Naphazoline	Protriptyline may decrease the antihypertensive activities of Naphazoline.	Approved
Naratriptan	The risk or severity of adverse effects can be increased when Protriptyline is combined with Naratriptan.	Approved, Investigational
Nefazodone	The risk or severity of adverse effects can be increased when Protriptyline is combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The serum concentration of Protriptyline can be increased when it is combined with Nelfinavir.	Approved
Nevirapine	The metabolism of Protriptyline can be decreased when combined with Nevirapine.	Approved
Nialamide	Nialamide may increase the serotonergic activities of Protriptyline.	Withdrawn
Nicardipine	The serum concentration of Nicardipine can be increased when it is combined with Protriptyline.	Approved
Nicorandil	Protriptyline may increase the hypotensive activities of Nicorandil.	Approved
Nifedipine	The serum concentration of Nifedipine can be increased when it is combined with Protriptyline.	Approved
Nilotinib	Protriptyline may increase the QTc-prolonging activities of Nilotinib.	Approved, Investigational
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Protriptyline.	Approved
Nitrazepam	The risk or severity of adverse effects can be increased when Nitrazepam is combined with Protriptyline.	Approved
Nitroaspirin	The serum concentration of Protriptyline can be increased when it is combined with Nitroaspirin.	Investigational
Nitrous oxide	The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Protriptyline.	Approved, Vet Approved
Nizatidine	The serum concentration of Nizatidine can be increased when it is combined with Protriptyline.	Approved
Norepinephrine	Protriptyline may decrease the antihypertensive activities of Norepinephrine.	Approved
Norflurane	The risk or severity of adverse effects can be increased when Protriptyline is combined with 1,1,1,2 Tetrafluoroethane.	Investigational
Normethadone	The risk or severity of adverse effects can be increased when Normethadone is combined with Protriptyline.	Approved, Illicit
Nortriptyline	The risk or severity of adverse effects can be increased when Protriptyline is combined with Nortriptyline.	Approved
Octamoxin	Octamoxin may increase the serotonergic activities of Protriptyline.	Withdrawn
Ofloxacin	Protriptyline may increase the QTc-prolonging activities of Ofloxacin.	Approved
Olanzapine	The serum concentration of Olanzapine can be increased when it is combined with Protriptyline.	Approved, Investigational
Olodaterol	The risk or severity of adverse effects can be increased when Protriptyline is combined with Olodaterol.	Approved
Olopatadine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Olopatadine.	Approved
Omapatrilat	The serum concentration of Protriptyline can be increased when it is combined with Omapatrilat.	Investigational
Ombitasvir	The serum concentration of Ombitasvir can be increased when it is combined with Protriptyline.	Approved
Ondansetron	Protriptyline may increase the QTc-prolonging activities of Ondansetron.	Approved
Opium	The risk or severity of adverse effects can be increased when Opium is combined with Protriptyline.	Approved, Illicit
Orciprenaline	The risk or severity of adverse effects can be increased when Protriptyline is combined with Orciprenaline.	Approved
Orphenadrine	Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.	Approved
Osanetant	The risk or severity of adverse effects can be increased when Osanetant is combined with Protriptyline.	Investigational
Osimertinib	The serum concentration of Osimertinib can be increased when it is combined with Protriptyline.	Approved
Otamixaban	The serum concentration of Protriptyline can be increased when it is combined with Otamixaban.	Investigational
Oxazepam	The risk or severity of adverse effects can be increased when Oxazepam is combined with Protriptyline.	Approved
Oxethazaine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Oxetacaine.	Investigational
Oxprenolol	The risk or severity of adverse effects can be increased when Oxprenolol is combined with Protriptyline.	Approved
Oxybuprocaine	The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Protriptyline.	Approved
Oxycodone	The risk or severity of adverse effects can be increased when Oxycodone is combined with Protriptyline.	Approved, Illicit, Investigational
Oxymetazoline	Protriptyline may decrease the antihypertensive activities of Oxymetazoline.	Approved
Oxymorphone	The risk or severity of adverse effects can be increased when Oxymorphone is combined with Protriptyline.	Approved, Investigational, Vet Approved
Paclitaxel	The serum concentration of Paclitaxel can be increased when it is combined with Protriptyline.	Approved, Vet Approved
Paliperidone	Protriptyline may decrease the antihypertensive activities of Paliperidone.	Approved
Palonosetron	Palonosetron may increase the serotonergic activities of Protriptyline.	Approved, Investigational
Panobinostat	The serum concentration of Protriptyline can be increased when it is combined with Panobinostat.	Approved, Investigational
Paraldehyde	Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.	Approved
Pargyline	Pargyline may increase the serotonergic activities of Protriptyline.	Approved
Paroxetine	The risk or severity of adverse effects can be increased when Paroxetine is combined with Protriptyline.	Approved, Investigational
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Protriptyline.	Approved
Peginterferon alfa-2b	The serum concentration of Protriptyline can be decreased when it is combined with Peginterferon alfa-2b.	Approved
Pentamidine	Protriptyline may increase the QTc-prolonging activities of Pentamidine.	Approved
Pentazocine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Protriptyline.	Approved, Vet Approved
Pentobarbital	The metabolism of Protriptyline can be increased when combined with Pentobarbital.	Approved, Vet Approved
Perampanel	Perampanel may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.	Approved
Perazine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Perazine.	Investigational
Perflutren	Protriptyline may increase the QTc-prolonging activities of Perflutren.	Approved
Pergolide	Protriptyline may decrease the antihypertensive activities of Pergolide.	Approved, Vet Approved, Withdrawn
Perindopril	The serum concentration of Protriptyline can be increased when it is combined with Perindopril.	Approved
Perospirone	The risk or severity of adverse effects can be increased when Perospirone is combined with Protriptyline.	Approved
Perphenazine	The risk or severity of adverse effects can be increased when Perphenazine is combined with Protriptyline.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Pethidine.	Approved
Phenelzine	Phenelzine may increase the serotonergic activities of Protriptyline.	Approved
Phenindione	Protriptyline may increase the anticoagulant activities of Phenindione.	Approved
Pheniprazine	Pheniprazine may increase the serotonergic activities of Protriptyline.	Withdrawn
Phenobarbital	The metabolism of Protriptyline can be increased when combined with Phenobarbital.	Approved
Phenoxyethanol	The risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Protriptyline.	Approved
Phenoxypropazine	Phenoxypropazine may increase the serotonergic activities of Protriptyline.	Withdrawn
Phenprocoumon	Protriptyline may increase the anticoagulant activities of Phenprocoumon.	Approved
Phentermine	Protriptyline may increase the stimulatory activities of Phentermine.	Approved, Illicit
Phenylephrine	Protriptyline may increase the vasopressor activities of Phenylephrine.	Approved
Phenylpropanolamine	Protriptyline may decrease the antihypertensive activities of Phenylpropanolamine.	Approved, Vet Approved, Withdrawn
Phenytoin	The serum concentration of Phenytoin can be increased when it is combined with Protriptyline.	Approved, Vet Approved
Phosphoramidon	The serum concentration of Protriptyline can be increased when it is combined with Phosphoramidon.	Experimental
Pimozide	Protriptyline may increase the QTc-prolonging activities of Pimozide.	Approved
Pipamperone	The risk or severity of adverse effects can be increased when Pipamperone is combined with Protriptyline.	Approved
Pipotiazine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Pipotiazine.	Approved
Pirbuterol	The risk or severity of adverse effects can be increased when Protriptyline is combined with Pirbuterol.	Approved
Piritramide	The risk or severity of adverse effects can be increased when Protriptyline is combined with Piritramide.	Investigational
Pirlindole	Pirlindole may increase the serotonergic activities of Protriptyline.	Approved
Pitavastatin	The serum concentration of Pitavastatin can be increased when it is combined with Protriptyline.	Approved
Pivhydrazine	Pivhydrazine may increase the serotonergic activities of Protriptyline.	Withdrawn
Pizotifen	The risk or severity of adverse effects can be increased when Protriptyline is combined with Pizotifen.	Approved
Pomalidomide	The serum concentration of Pomalidomide can be increased when it is combined with Protriptyline.	Approved
Ponatinib	The serum concentration of Ponatinib can be increased when it is combined with Protriptyline.	Approved
Pramipexole	Protriptyline may increase the sedative activities of Pramipexole.	Approved, Investigational
Pramocaine	The risk or severity of adverse effects can be increased when Pramocaine is combined with Protriptyline.	Approved
Pravastatin	The serum concentration of Pravastatin can be increased when it is combined with Protriptyline.	Approved
Prazepam	The risk or severity of adverse effects can be increased when Prazepam is combined with Protriptyline.	Approved, Illicit
Prazosin	The serum concentration of Prazosin can be increased when it is combined with Protriptyline.	Approved
Prednisolone	The serum concentration of Prednisolone can be increased when it is combined with Protriptyline.	Approved, Vet Approved
Prednisone	The serum concentration of Prednisone can be increased when it is combined with Protriptyline.	Approved, Vet Approved
Pregabalin	The risk or severity of adverse effects can be increased when Pregabalin is combined with Protriptyline.	Approved, Illicit, Investigational
Prilocaine	The risk or severity of adverse effects can be increased when Prilocaine is combined with Protriptyline.	Approved
Primaquine	Protriptyline may increase the QTc-prolonging activities of Primaquine.	Approved
Primidone	The metabolism of Protriptyline can be increased when combined with Primidone.	Approved, Vet Approved
Prinomastat	The serum concentration of Protriptyline can be increased when it is combined with Prinomastat.	Investigational
Procainamide	Protriptyline may increase the QTc-prolonging activities of Procainamide.	Approved
Procaine	The risk or severity of adverse effects can be increased when Procaine is combined with Protriptyline.	Approved, Investigational, Vet Approved
Procarbazine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Procarbazine.	Approved
Procaterol	The risk or severity of adverse effects can be increased when Protriptyline is combined with Procaterol.	Approved
Prochlorperazine	The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Protriptyline.	Approved, Vet Approved
Progesterone	The serum concentration of Progesterone can be increased when it is combined with Protriptyline.	Approved, Vet Approved
Promazine	Protriptyline may increase the QTc-prolonging activities of Promazine.	Approved, Vet Approved
Promethazine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Promethazine.	Approved
Propafenone	Protriptyline may increase the QTc-prolonging activities of Propafenone.	Approved
Proparacaine	The risk or severity of adverse effects can be increased when Proparacaine is combined with Protriptyline.	Approved, Vet Approved
Propericiazine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Propericiazine.	Approved
Propofol	The risk or severity of adverse effects can be increased when Propofol is combined with Protriptyline.	Approved, Investigational, Vet Approved
Propoxycaine	The risk or severity of adverse effects can be increased when Propoxycaine is combined with Protriptyline.	Approved
Propranolol	The serum concentration of Propranolol can be increased when it is combined with Protriptyline.	Approved, Investigational
Prothipendyl	The risk or severity of adverse effects can be increased when Protriptyline is combined with Prothipendyl.	Investigational
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Protriptyline.	Approved
PSD502	The risk or severity of adverse effects can be increased when PSD502 is combined with Protriptyline.	Investigational
Pseudoephedrine	Protriptyline may decrease the antihypertensive activities of Pseudoephedrine.	Approved
Quazepam	The risk or severity of adverse effects can be increased when Quazepam is combined with Protriptyline.	Approved, Illicit
Quetiapine	Protriptyline may increase the QTc-prolonging activities of Quetiapine.	Approved
Quinapril	The serum concentration of Protriptyline can be increased when it is combined with Quinapril.	Approved, Investigational
Quinidine	Protriptyline may increase the QTc-prolonging activities of Quinidine.	Approved
Quinine	Protriptyline may increase the QTc-prolonging activities of Quinine.	Approved
Racecadotril	The serum concentration of Protriptyline can be increased when it is combined with Racecadotril.	Investigational
Raclopride	The risk or severity of adverse effects can be increased when Protriptyline is combined with Raclopride.	Investigational
Ramelteon	The risk or severity of adverse effects can be increased when Protriptyline is combined with Ramelteon.	Approved, Investigational
Ramipril	The serum concentration of Protriptyline can be increased when it is combined with Ramipril.	Approved
Ranitidine	The serum concentration of Ranitidine can be increased when it is combined with Protriptyline.	Approved
Ranolazine	The serum concentration of Ranolazine can be increased when it is combined with Protriptyline.	Approved, Investigational
Rasagiline	Rasagiline may increase the serotonergic activities of Protriptyline.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Remifentanil is combined with Protriptyline.	Approved
Remikiren	The serum concentration of Protriptyline can be increased when it is combined with Remikiren.	Approved
Remoxipride	The risk or severity of adverse effects can be increased when Remoxipride is combined with Protriptyline.	Approved, Withdrawn
Reserpine	The serum concentration of Reserpine can be increased when it is combined with Protriptyline.	Approved
Rifampicin	The serum concentration of Rifampicin can be increased when it is combined with Protriptyline.	Approved
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Protriptyline.	Approved, Investigational
Risperidone	Protriptyline may decrease the antihypertensive activities of Risperidone.	Approved, Investigational
Ritanserin	The risk or severity of adverse effects can be increased when Protriptyline is combined with Ritanserin.	Investigational
Ritobegron	Protriptyline may increase the stimulatory activities of Ritobegron.	Investigational
Ritodrine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Ritodrine.	Approved
Ritonavir	The metabolism of Protriptyline can be decreased when combined with Ritonavir.	Approved, Investigational
Rivaroxaban	The serum concentration of Protriptyline can be increased when it is combined with Rivaroxaban.	Approved
Rizatriptan	The risk or severity of adverse effects can be increased when Protriptyline is combined with Rizatriptan.	Approved
Rolapitant	The metabolism of Protriptyline can be decreased when combined with Rolapitant.	Approved
Romidepsin	The serum concentration of Romidepsin can be increased when it is combined with Protriptyline.	Approved, Investigational
Romifidine	The risk or severity of adverse effects can be increased when Romifidine is combined with Protriptyline.	Vet Approved
Ropinirole	Protriptyline may increase the sedative activities of Ropinirole.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Ropivacaine is combined with Protriptyline.	Approved
Rotigotine	Protriptyline may increase the sedative activities of Rotigotine.	Approved
Rufinamide	The risk or severity of adverse effects can be increased when Rufinamide is combined with Protriptyline.	Approved
Safrazine	Safrazine may increase the serotonergic activities of Protriptyline.	Withdrawn
Salbutamol	The risk or severity of adverse effects can be increased when Protriptyline is combined with Salbutamol.	Approved, Vet Approved
Salicylic acid	The serum concentration of Salicylic acid can be increased when it is combined with Protriptyline.	Approved, Vet Approved
Salmeterol	The risk or severity of adverse effects can be increased when Protriptyline is combined with Salmeterol.	Approved
Saquinavir	The serum concentration of Protriptyline can be increased when it is combined with Saquinavir.	Approved, Investigational
Saxagliptin	The serum concentration of Protriptyline can be increased when it is combined with Saxagliptin.	Approved
Scopolamine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Scopolamine.	Approved
Secobarbital	The metabolism of Protriptyline can be increased when combined with Secobarbital.	Approved, Vet Approved
Selegiline	Selegiline may increase the serotonergic activities of Protriptyline.	Approved, Investigational, Vet Approved
Selexipag	The serum concentration of Selexipag can be increased when it is combined with Protriptyline.	Approved
Sepranolone	The risk or severity of adverse effects can be increased when Protriptyline is combined with Uc1010.	Investigational
Sertindole	The risk or severity of adverse effects can be increased when Sertindole is combined with Protriptyline.	Approved, Withdrawn
Sertraline	The risk or severity of adverse effects can be increased when Sertraline is combined with Protriptyline.	Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Sevoflurane is combined with Protriptyline.	Approved, Vet Approved
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Protriptyline.	Approved
Simeprevir	The serum concentration of Protriptyline can be increased when it is combined with Simeprevir.	Approved
Sitagliptin	The serum concentration of Protriptyline can be increased when it is combined with Sitagliptin.	Approved, Investigational
Sodium oxybate	Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.	Approved
Sofosbuvir	The serum concentration of Sofosbuvir can be increased when it is combined with Protriptyline.	Approved
Sorafenib	The serum concentration of Sorafenib can be increased when it is combined with Protriptyline.	Approved, Investigational
Sotalol	Protriptyline may increase the QTc-prolonging activities of Sotalol.	Approved
Sparfloxacin	The serum concentration of Sparfloxacin can be increased when it is combined with Protriptyline.	Approved
Sphingosine	The serum concentration of Sphingosine can be increased when it is combined with Protriptyline.	Experimental
Spirapril	The serum concentration of Protriptyline can be increased when it is combined with Spirapril.	Approved
St. John's Wort	The metabolism of Protriptyline can be increased when combined with St. John's Wort.	Nutraceutical
Stiripentol	The metabolism of Protriptyline can be decreased when combined with Stiripentol.	Approved
Sufentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Protriptyline.	Approved, Investigational
Sulfisoxazole	Protriptyline may increase the QTc-prolonging activities of Sulfisoxazole.	Approved, Vet Approved
Sulpiride	The risk or severity of adverse effects can be increased when Sulpiride is combined with Protriptyline.	Approved
Sumatriptan	The risk or severity of adverse effects can be increased when Protriptyline is combined with Sumatriptan.	Approved, Investigational
Suvorexant	Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.	Approved
Tacrolimus	The serum concentration of Tacrolimus can be increased when it is combined with Protriptyline.	Approved, Investigational
Tamoxifen	The serum concentration of Tamoxifen can be increased when it is combined with Protriptyline.	Approved
Tandospirone	The risk or severity of adverse effects can be increased when Protriptyline is combined with Tandospirone.	Investigational
Tapentadol	Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.	Approved
Tasimelteon	The risk or severity of adverse effects can be increased when Protriptyline is combined with Tasimelteon.	Approved
Taurocholic Acid	The serum concentration of Taurocholic Acid can be increased when it is combined with Protriptyline.	Experimental
Technetium Tc-99m sestamibi	The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Protriptyline.	Approved
Tedizolid Phosphate	Tedizolid Phosphate may increase the serotonergic activities of Protriptyline.	Approved
Telaprevir	The serum concentration of Protriptyline can be increased when it is combined with Telaprevir.	Withdrawn
Telavancin	Protriptyline may increase the QTc-prolonging activities of Telavancin.	Approved
Telithromycin	Protriptyline may increase the QTc-prolonging activities of Telithromycin.	Approved
Temazepam	The risk or severity of adverse effects can be increased when Temazepam is combined with Protriptyline.	Approved
Temocapril	The serum concentration of Protriptyline can be increased when it is combined with Temocapril.	Experimental, Investigational
Temsirolimus	The serum concentration of Temsirolimus can be increased when it is combined with Protriptyline.	Approved
Terbinafine	The metabolism of Protriptyline can be decreased when combined with Terbinafine.	Approved, Investigational, Vet Approved
Terbutaline	The risk or severity of adverse effects can be increased when Protriptyline is combined with Terbutaline.	Approved
Tetrabenazine	Protriptyline may increase the QTc-prolonging activities of Tetrabenazine.	Approved
Tetracaine	The risk or severity of adverse effects can be increased when Tetracaine is combined with Protriptyline.	Approved, Vet Approved
Tetrodotoxin	The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Protriptyline.	Investigational
Thalidomide	Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.	Approved, Investigational, Withdrawn
Thiamylal	The metabolism of Protriptyline can be increased when combined with Thiamylal.	Approved, Vet Approved
Thiopental	The metabolism of Protriptyline can be increased when combined with Thiopental.	Approved, Vet Approved
Thioproperazine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Thioproperazine.	Approved
Thioridazine	Protriptyline may increase the QTc-prolonging activities of Thioridazine.	Withdrawn
Thiorphan	The serum concentration of Protriptyline can be increased when it is combined with Thiorphan.	Experimental
Thiothixene	The risk or severity of adverse effects can be increased when Thiothixene is combined with Protriptyline.	Approved
Thyroid, porcine	Thyroid, porcine may increase the arrhythmogenic activities of Protriptyline.	Approved
Tiagabine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Tiagabine.	Approved
Tiapride	The risk or severity of adverse effects can be increased when Protriptyline is combined with Tiapride.	Approved, Investigational
Ticagrelor	The serum concentration of Ticagrelor can be increased when it is combined with Protriptyline.	Approved
Ticlopidine	The metabolism of Protriptyline can be decreased when combined with Ticlopidine.	Approved
Tiletamine	The risk or severity of adverse effects can be increased when Tiletamine is combined with Protriptyline.	Vet Approved
Timolol	The serum concentration of Timolol can be increased when it is combined with Protriptyline.	Approved
Tipranavir	The metabolism of Protriptyline can be decreased when combined with Tipranavir.	Approved, Investigational
Tizanidine	Protriptyline may decrease the antihypertensive activities of Tizanidine.	Approved
Tolcapone	The risk or severity of adverse effects can be increased when Tolcapone is combined with Protriptyline.	Approved, Withdrawn
Toloxatone	Toloxatone may increase the serotonergic activities of Protriptyline.	Approved
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Protriptyline.	Approved
Topiramate	The risk or severity of adverse effects can be increased when Topiramate is combined with Protriptyline.	Approved
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Protriptyline.	Approved, Investigational
Toremifene	Protriptyline may increase the QTc-prolonging activities of Toremifene.	Approved, Investigational
Tramadol	Protriptyline may increase the neuroexcitatory activities of Tramadol.	Approved, Investigational
Trandolapril	The serum concentration of Protriptyline can be increased when it is combined with Trandolapril.	Approved
Trans-2-Phenylcyclopropylamine	Trans-2-Phenylcyclopropylamine may increase the serotonergic activities of Protriptyline.	Experimental
Tranylcypromine	Tranylcypromine may increase the serotonergic activities of Protriptyline.	Approved
Trastuzumab emtansine	The serum concentration of Trastuzumab emtansine can be increased when it is combined with Protriptyline.	Approved
Trazodone	The risk or severity of adverse effects can be increased when Protriptyline is combined with Trazodone.	Approved, Investigational
Triazolam	The risk or severity of adverse effects can be increased when Triazolam is combined with Protriptyline.	Approved
Trifluoperazine	The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Protriptyline.	Approved
Triflupromazine	The risk or severity of adverse effects can be increased when Triflupromazine is combined with Protriptyline.	Approved, Vet Approved
Trimipramine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Trimipramine.	Approved
Triprolidine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Triprolidine.	Approved
Tropisetron	Tropisetron may increase the serotonergic activities of Protriptyline.	Approved, Investigational
Ubenimex	The serum concentration of Protriptyline can be increased when it is combined with Ubenimex.	Experimental
Ulinastatin	The serum concentration of Protriptyline can be increased when it is combined with Ulinastatin.	Investigational
Ulipristal	The serum concentration of Ulipristal can be increased when it is combined with Protriptyline.	Approved
Umeclidinium	The serum concentration of Umeclidinium can be increased when it is combined with Protriptyline.	Approved
Valproic Acid	The serum concentration of Protriptyline can be increased when it is combined with Valproic Acid.	Approved, Investigational
Vandetanib	Protriptyline may increase the QTc-prolonging activities of Vandetanib.	Approved
Vecuronium	The serum concentration of Vecuronium can be increased when it is combined with Protriptyline.	Approved
Vemurafenib	Protriptyline may increase the QTc-prolonging activities of Vemurafenib.	Approved
Venetoclax	The serum concentration of Venetoclax can be increased when it is combined with Protriptyline.	Approved
Venlafaxine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Protriptyline.	Approved
Verapamil	The serum concentration of Verapamil can be increased when it is combined with Protriptyline.	Approved
Vigabatrin	The risk or severity of adverse effects can be increased when Protriptyline is combined with Vigabatrin.	Approved
Vilanterol	The risk or severity of adverse effects can be increased when Protriptyline is combined with Vilanterol.	Approved
Vilazodone	The risk or severity of adverse effects can be increased when Protriptyline is combined with Vilazodone.	Approved
Vildagliptin	The serum concentration of Protriptyline can be increased when it is combined with Vildagliptin.	Approved, Investigational
Vinblastine	The serum concentration of Vinblastine can be increased when it is combined with Protriptyline.	Approved
Vincristine	The serum concentration of Vincristine can be increased when it is combined with Protriptyline.	Approved, Investigational
Vismodegib	The serum concentration of Vismodegib can be increased when it is combined with Protriptyline.	Approved
Vortioxetine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Vortioxetine.	Approved
Warfarin	Protriptyline may increase the anticoagulant activities of Warfarin.	Approved
Ximelagatran	The serum concentration of Protriptyline can be increased when it is combined with Ximelagatran.	Approved, Investigational, Withdrawn
Xylazine	The risk or severity of adverse effects can be increased when Xylazine is combined with Protriptyline.	Vet Approved
Xylometazoline	Protriptyline may decrease the antihypertensive activities of Xylometazoline.	Approved
Yohimbine	The serum concentration of Yohimbine can be increased when it is combined with Protriptyline.	Approved, Vet Approved
Zaleplon	The risk or severity of adverse effects can be increased when Zaleplon is combined with Protriptyline.	Approved, Illicit, Investigational
Ziconotide	The risk or severity of adverse effects can be increased when Protriptyline is combined with Ziconotide.	Approved
Zidovudine	The serum concentration of Zidovudine can be increased when it is combined with Protriptyline.	Approved
Zimelidine	The risk or severity of adverse effects can be increased when Protriptyline is combined with Zimelidine.	Withdrawn
Ziprasidone	Protriptyline may increase the QTc-prolonging activities of Ziprasidone.	Approved
Zolazepam	The risk or severity of adverse effects can be increased when Zolazepam is combined with Protriptyline.	Vet Approved
Zolmitriptan	The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Protriptyline.	Approved, Investigational
Zolpidem	Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.	Approved
Zonisamide	The risk or severity of adverse effects can be increased when Protriptyline is combined with Zonisamide.	Approved, Investigational
Zopiclone	The risk or severity of adverse effects can be increased when Zopiclone is combined with Protriptyline.	Approved
Zotepine	The risk or severity of adverse effects can be increased when Zotepine is combined with Protriptyline.	Approved
Zuclopenthixol	Protriptyline may increase the QTc-prolonging activities of Zuclopenthixol.	Approved, Investigational

Food Interactions

Not Available

References

Synthesis Reference

Not Available

General References

Not Available

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB14488
KEGG Compound	C07408
PubChem Compound	4976
PubChem Substance	46505128
ChemSpider	4805
BindingDB	50176062
ChEBI	8597
ChEMBL	CHEMBL668
Therapeutic Targets Database	DAP000863
PharmGKB	PA451168
Drug Product Database	9430
Drugs.com	http://www.drugs.com/cdi/protriptyline.html
PDRhealth	http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/viv1617.shtml
Wikipedia	Protriptyline

ATC Codes

N06AA11 — Protriptyline

AHFS Codes

Not Available

PDB Entries

Not Available

FDA label

Not Available

MSDS

Not Available

Clinical Trials

Phase	Status	Purpose	Conditions	Count
Not Available	Completed	Treatment	Depressive State	1

Pharmacoeconomics

Manufacturers

Sanofi aventis us llc
Pfizer laboratories div pfizer inc
Roxane laboratories inc
Sigmapharm laboratories llc
Odyssey pharmaceuticals inc

Packagers

Dosage forms

Form	Route	Strength
Tablet	Oral	10 mg/1
Tablet	Oral	5 mg/1
Tablet, film coated	Oral	10 mg/1
Tablet, film coated	Oral	5 mg/1
Tablet	Oral	10 mg

Prices

Unit description	Cost	Unit
Tofranil-PM 30 125 mg capsule Bottle	588.33USD	bottle
Tofranil-PM 30 150 mg capsule Bottle	588.33USD	bottle
Tofranil-PM 30 75 mg capsule Bottle	588.33USD	bottle
Tofranil 30 50 mg tablet Bottle	185.09USD	bottle
Tofranil-pm 100 mg capsule	19.23USD	capsule
Tofranil-pm 150 mg capsule	18.86USD	capsule
Tofranil-pm 75 mg capsule	18.86USD	capsule
Tofranil-pm 125 mg capsule	18.68USD	capsule
Anafranil 25 mg capsule	13.51USD	capsule
Anafranil 50 mg capsule	13.51USD	capsule
Anafranil 75 mg capsule	13.24USD	capsule
Tofranil 50 mg tablet	6.64USD	tablet
Norpramin 150 mg tablet	6.23USD	tablet
Surmontil 100 mg capsule	5.92USD	capsule
Tofranil 25 mg tablet	4.97USD	tablet
Tofranil 10 mg tablet	4.73USD	tablet
Norpramin 100 mg tablet	4.27USD	tablet
Surmontil 50 mg capsule	4.15USD	capsule
Vivactil 10 mg tablet	4.05USD	tablet
Norpramin 75 mg tablet	3.27USD	tablet
Protriptyline hcl 10 mg tablet	3.07USD	tablet
Vivactil 5 mg tablet	2.86USD	tablet
Norpramin 50 mg tablet	2.59USD	tablet
Surmontil 25 mg capsule	2.49USD	capsule
Protriptyline hcl 5 mg tablet	2.12USD	tablet
Norpramin 25 mg tablet	1.4USD	tablet
Norpramin 10 mg tablet	1.16USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	169-171 °C (Protriptyline HCl)	Not Available
water solubility	1.04 mg/L	Not Available
logP	4.7	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.000231 mg/mL	ALOGPS
logP	4.65	ALOGPS
logP	4.5	ChemAxon
logS	-6.1	ALOGPS
pKa (Strongest Basic)	10.54	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	1	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	12.03 Å²	ChemAxon
Rotatable Bond Count	4	ChemAxon
Refractivity	87.3 m³·mol^-1	ChemAxon
Polarizability	31.6 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	1.0
Blood Brain Barrier	+	0.9862
Caco-2 permeable	+	0.7821
P-glycoprotein substrate	Substrate	0.7406
P-glycoprotein inhibitor I	Inhibitor	0.8563
P-glycoprotein inhibitor II	Inhibitor	0.5597
Renal organic cation transporter	Inhibitor	0.6622
CYP450 2C9 substrate	Non-substrate	0.7206
CYP450 2D6 substrate	Substrate	0.9034
CYP450 3A4 substrate	Substrate	0.5285
CYP450 1A2 substrate	Non-inhibitor	0.7595
CYP450 2C9 inhibitor	Non-inhibitor	0.9071
CYP450 2D6 inhibitor	Inhibitor	0.8933
CYP450 2C19 inhibitor	Non-inhibitor	0.9026
CYP450 3A4 inhibitor	Inhibitor	0.641
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.7512
Ames test	Non AMES toxic	0.6
Carcinogenicity	Non-carcinogens	0.9322
Biodegradation	Not ready biodegradable	0.7732
Rat acute toxicity	3.0087 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.736
hERG inhibition (predictor II)	Inhibitor	0.8132

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
Predicted GC-MS	Predicted GC-MS Spectrum - GC-MS	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available
MS	Mass Spectrum (Electron Ionization)	splash10-006x-8910000000-ec599ee02d998905757e	View in MoNA

Taxonomy

Description

This compound belongs to the class of chemical entities known as dibenzocycloheptenes. These are compounds containing a dibenzocycloheptene moiety, which consists of two benzene rings connected by a cycloheptene ring.

Kingdom

Super Class

Class

Sub Class

Direct Parent

Alternative Parents

Aralkylamines / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives

Substituents

Dibenzocycloheptene / Aralkylamine / Secondary amine / Secondary aliphatic amine / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative / Organonitrogen compound / Amine / Aromatic homopolycyclic compound

Molecular Framework

Aromatic homopolycyclic compounds

External Descriptors

organic tricyclic compound (CHEBI:8597 )

Targets

Details

1. Sodium-dependent noradrenaline transporter

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Norepinephrine:sodium symporter activity
Specific Function:: Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:: SLC6A2
Uniprot ID:: P23975
Uniprot Name:: Sodium-dependent noradrenaline transporter
Molecular Weight:: 69331.42 Da

References

Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Cheetham SC, Viggers JA, Butler SA, Prow MR, Heal DJ: [3H]nisoxetine--a radioligand for noradrenaline reuptake sites: correlation with inhibition of [3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments. Neuropharmacology. 1996 Jan;35(1):63-70. [PubMed:8684598 ]

Details

2. Sodium-dependent serotonin transporter

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Serotonin:sodium symporter activity
Specific Function:: Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:: SLC6A4
Uniprot ID:: P31645
Uniprot Name:: Sodium-dependent serotonin transporter
Molecular Weight:: 70324.165 Da

References

McDougle CJ, Epperson CN, Price LH, Gelernter J: Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder. Mol Psychiatry. 1998 May;3(3):270-3. [PubMed:9672904 ]
Rouillon F, Blachier C, Dreyfus JP, Bouhassira M, Allicar MP: [Pharmaco-epidemiologic study of the use of antidepressant drugs in the general population]. Encephale. 1996 May;22 Spec No 1:39-48. [PubMed:8767026 ]
Frazer A, Daws LC: Serotonin transporter function in vivo: assessment by chronoamperometry. Ann N Y Acad Sci. 1998 Dec 15;861:217-29. [PubMed:9928259 ]
Daws LC, Toney GM, Gerhardt GA, Frazer A: In vivo chronoamperometric measures of extracellular serotonin clearance in rat dorsal hippocampus: contribution of serotonin and norepinephrine transporters. J Pharmacol Exp Ther. 1998 Aug;286(2):967-76. [PubMed:9694957 ]
Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kovachich GB, Aronson CE, Brunswick DJ: Effect of repeated administration of antidepressants on serotonin uptake sites in limbic and neocortical structures of rat brain determined by quantitative autoradiography. Neuropsychopharmacology. 1992 Dec;7(4):317-24. [PubMed:1476595 ]

Enzymes

Details

1. Cytochrome P450 2D6

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Steroid hydroxylase activity
Specific Function:: Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:: CYP2D6
Uniprot ID:: P10635
Uniprot Name:: Cytochrome P450 2D6
Molecular Weight:: 55768.94 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Details

1. Multidrug resistance protein 1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Xenobiotic-transporting atpase activity
Specific Function:: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:: ABCB1
Uniprot ID:: P08183
Uniprot Name:: Multidrug resistance protein 1
Molecular Weight:: 141477.255 Da

References

Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. [PubMed:11082465 ]

Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 10:26

Structure for DB00344 (Protriptyline)

Targets

References

References

Enzymes

References

Transporters

References